Enhancing Utrophin Expression in Cell by Inducing Mutations Within Utrophin Regulatory Elements and Therapeutic Use Thereof
AssigneesGenethon, Universite D'Evry Val D'Essonne, Institut National de la Sante et de la Recherche Medicale
InventorsMario Amendola, Simon Guiraud
Life of this patent
Estimating the term…
Abstract
The invention relates to a composition for enhancing utrophin expression in cell by inducing mutations within a target sequence comprising a utrophin repressor binding site using a gene editing enzyme and the use thereof for the treatment of a dy-strophinopathy.
Claims21
1-18. (canceled)
A method for enhancing utrophin expression in a cell, comprising introducing into a cell a composition comprising at least one gene editing enzyme capable of inducing site-specific mutation(s) within a target sequence comprising at least one repressor binding site of utrophin gene selected from the group consisting of:
- Ets-2-repressor factor (ERF) binding sites, homeobox protein engrailed-1 (EN1) binding site 2, Let7c binding site and miR-196b binding site, wherein said mutation(s) disrupt the repressor binding site without deleting the whole repressor binding site sequence.
A composition for enhancing utrophin expression comprising at least one gene editing enzyme capable of inducing site-specific mutation within a target sequence comprising a repressor binding site of utrophin gene selected from the group consisting of:
- Ets-2-repressor factor (ERF) binding sites consisting of sequence CGGAA, homeobox protein engrailed-1 (EN1) binding site 2 consisting of sequence GTAGTGG, Let7c binding site consisting of SEQ ID NO:
- 1 and miR-196b binding site consisting of SEQ ID NO:
- 2 and wherein the mutation(s) disrupt the repressor binding site without deleting the whole repressor binding site sequences.
An engineered cell comprising site-specific mutation(s) within at least one target sequence comprising repressor binding site of utrophin gene selected from the group consisting of:
- Ets-2-repressor factor (ERF) binding sites, homeobox protein engrailed-1 (EN1) binding site 2, Let7c binding site and miR-196b binding site, wherein the mutations disrupt repressor binding site without deleting the whole repressor binding site sequence.
Dependencies are inferred from the claim text.